secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0000950170-25-046948
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen and Fortis amend agreements, extend option exercise deadline to Dec 31, 2027
--------------------------------------------------------------------------------

- Amendments No.1 to Evaluation Agreement and Option Agreement & Plan of Merger executed March 28, 2025.
- Original agreements dated June 6, 2024, as amended and restated from May 5, 2023.
- Option exercise deadline under both agreements extended to December 31, 2027.
- Full text of amendments to be filed with FibroGen's Q1 2025 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025046948/0000950170-25-046948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025046948/fgen-20250328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer